Can you take Guanfacine with Repotrectinib?

Repotrectinib has a moderate potential interaction with Asthma.

Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.

guanFACINE has a moderate potential interaction with Cerebrovascular Insufficiency.

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.

Repotrectinib has a moderate potential interaction with COPD.

Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.

guanFACINE has a moderate potential interaction with Depression.

Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.

guanFACINE has a moderate potential interaction with Heart Block.

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.

guanFACINE has a moderate potential interaction with Hyperkinetic Syndrome of Childhood.

The safety and effectiveness of guanfacine in children under 12 years of age has not been demonstrated and its use in this age group is not recommended. However, there have been some spontaneous postmarketing reports of mania and aggressive behavioral changes in pediatric patients with attention- deficit hyperactivity disorder (ADHD) that received this drug. All patients had medical or family risks of bipolar disorder, and all of them recovered after treatment discontinuation. Hallucinations have also been reported in pediatric patients receiving guanfacine for the treatment of ADHD.

guanFACINE has a moderate potential interaction with Hypotension.

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.

Repotrectinib has a moderate potential interaction with Interstitial Lung Disease.

Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.

guanFACINE has a moderate potential interaction with Ischemic Heart Disease.

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.

guanFACINE has a moderate potential interaction with Liver Disease.

Normally, approximately 50% of a guanfacine dose is eliminated unchanged by the kidney and the rest metabolized by the liver. However, neither the parent drug nor its metabolites accumulate significantly during chronic dosing in patients with severe renal impairment due to increased hepatic metabolism of the drug in these patients. Thus, initial dosage adjustments are generally not necessary in renal impairment. Dosage titration, however, should be made cautiously if hepatic function is also compromised. The pharmacokinetics of guanfacine has not been studied in patients with liver disease. The manufacturer recommends caution when the drug is used in such patients.

Repotrectinib has a moderate potential interaction with Liver Disease.

Repotrectinib can cause hepatotoxicity; this may be considered in patients with liver problems. The effect of moderate or severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal and any AST) on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with moderate or severe liver dysfunction.

Repotrectinib has a moderate potential interaction with Neurological Disorders.

Repotrectinib can cause central nervous system (CNS) adverse reactions including dizziness, ataxia, cognitive disorders, mood disorders, and sleep disorders. This may be considered in patients with neurological problems. Patients should be advised to contact their health care provider for new/worsening CNS symptoms.

guanFACINE has a moderate potential interaction with Peripheral Arterial Disease.

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.

guanFACINE has a moderate potential interaction with Renal Dysfunction.

Normally, approximately 50% of a guanfacine dose is eliminated unchanged by the kidney and the rest metabolized by the liver. However, neither the parent drug nor its metabolites accumulate significantly during chronic dosing in patients with severe renal impairment due to increased hepatic metabolism of the drug in these patients. Thus, initial dosage adjustments are generally not necessary in renal impairment. Dosage titration, however, should be made cautiously if hepatic function is also compromised. The pharmacokinetics of guanfacine has not been studied in patients with liver disease. The manufacturer recommends caution when the drug is used in such patients.

Repotrectinib has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal dysfunction, kidney failure (estimated GFR less than 30 mL/min), or dialysis on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with severe renal dysfunction or kidney failure or in patients on dialysis.

guanFACINE has a moderate potential interaction with Sinus Node Dysfunction.

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.